Objective: Pretreatment with lithium (Li) is associated with an increased residence time of radioactive iodine (RAI) in differentiated thyroid cancer (DTC) metastases.
| INTRODUC TI ON
The routine management of patients with differentiated thyroid cancer (DTC) presenting with distant metastases consists of total thyroidectomy with or without lymph node dissection, as appropriate, followed by therapy with radioiodine (RAI). RAI dosage could be administered as either (a) empiric fixed dose, which for high-risk patients with distant metastases, varies between 100 to 200 mCi or (b) based on dosimetry calculations enabling therapy with the maximum safe activity not exceeding 200 rads to the bone marrow. [1] [2] [3] The dosimetry-based individualized approach is especially important for older patients and children in whom empiric activity might exceed safe radiation limits. 4, 5 Administration of RAI requires thyrotropin (TSH) stimulation which may be achieved by two possible methods:
(a) thyroid hormone withdrawal (THW) to provoke endogenous TSH elevation or (b) exogenous stimulation by recombinant human TSH (rhTSH).
While rhTSH is approved and widely used for thyroid remnant ablation, there is still a controversy regarding its use in preparation for RAI treatment of distant metastases. In fact, current 2015
American Thyroid Association guidelines state that "in patients with ATA high risk DTC with attendant higher risks of diseaserelated mortality and morbidity, more controlled data from longterm outcome studies are needed before rhTSH preparation for RAI adjuvant treatment can be recommended. (No recommendation, Insufficient evidence)". 1 The potential benefit of using rhTSHaided RAI treatment is to avoid the effects of hypothyroidism that might be poorly tolerated especially by older individuals or patients with comorbidities. The additional advantage is more rapid whole-body clearance of RAI after rhTSH, which results in a lower total-body, bone marrow and gastrointestinal radiation exposure for a given administered activity. 6 On the other hand, there are several studies showing lower RAI uptake in metastatic lesions after preparation with rhTSH compared with THW. [7] [8] [9] [10] Therefore, rhTSH-aided therapy for metastatic thyroid cancer is currently not FDA approved, and its administration is performed off-label or via compassionate use programme.
Treatment with lithium has been associated with increased uptake and residence time of RAI in metastatic lesions. 11 The initial pilot study involving 15 patients with thyroid cancer metastases, performed in the National Institutes of Health, revealed that the mean lithium-induced increase in the biological retention half-life in tumours was 50% and occurred in at least 1 lesion in each patient leading to increased accumulation of RAI in metastatic lesions by an average of 2.3 ± 0.6 times. 11 The potential translation of these findings to the effect on patients' outcomes is unknown. Therefore, current 2015 American Thyroid Association guidelines state that the data are insufficient to recommend lithium therapy as an adjunct to RAI treatment. 1 These unknowns formed the rationale for our study, which compared the relative efficacy of three methods of preparation for RAI therapy of metastatic DTC: (a) THW;
(b) THW with pretreatment with therapeutic dose of lithium for 7 days; and (c) rhTSH.
| ME THODS

| Study design and population
We performed a cohort study at the National Institute of Health (NIH) including patients with DTC presenting with RAI-avid distant metastases, who after total thyroidectomy underwent repeated dosimetry-based RAI therapies under the preparation with THW and administration of lithium carbonate for 7 days before RAI, and followed for median 5.7 (3.5-9.5) years. We retrospectively analysed 
| Exposures
The NIH cohort was prepared for each radioactive iodine treatment with thyroid hormone withdrawal for 6 weeks-with triiodothyronine supplementation for the first 4 weeks, and no thyroid hormone therapy and low-iodine diet for the last 2 weeks of this period. The patients were admitted to the hospital for 7-10 days and treated with lithium carbonate 600 mg orally as a loading dose followed by 300 mg po BID with dose adjustments to target serum Li level of 0.6-1.2 mEq/mL. Lithium levels were measured daily. Therapeutic RAI dosage not exceeding a maximum tolerated activity (MTA) was determined by a standard dosimetry protocol. [12] [13] [14] Briefly, calcula- The control groups were prepared for RAI therapy with either rhTSH (rhTSH group) 0.9 mg i.m on 2 consecutive days or 4-6 weeks of thyroid hormone withdrawal (THW group) and underwent similar dosimetry calculations of MTA before rhTSH-or THW-aided RAI therapy.
14 All patients adhered to a low-iodine diet for at least 2 weeks prior to the treatment with the goal urine iodine of <100 mcg/L.
| Covariates
Information on age at diagnosis, gender, histology subtype, TNM status, number of metastatic lymph nodes involved, completeness of surgical resection, and RAI dose was extracted from medical records. Distant metastases were categorized into: (a) only micronodular pulmonary metastases, (b) pulmonary micro-and macrometastases without other organs involved, (c) bone metastases (including spine) with or without pulmonary metastases, and (d) multiple organ involvement with additional metastatic foci in the skin, brain, and pleura.
| Outcomes
The primary outcomes were overall survival (OS) and progressionfree survival (PFS). PFS was defined as time from initial diagnosis to the first evidence of structural disease progression, defined per RECIST 1.1 criteria as at least a 20% increase in the sum of three diameters of target lesions taking as a reference the smallest sum on the study and an absolute increase of at least 5 mm when a total sum is very small or appearance of one or more new lesions. 15, 16 To objectively assess overall survival, the individual medical records of patients with thyroid cancer who died during follow-up were reviewed.
The secondary outcome was the best overall response to treatment, which according to 2015 ATA guidelines was categorized as: 
| Statistical analysis
The baseline demographics and clinical characteristics were summarized using either median with interquartile range (IQR) or proportions as appropriate and were compared between the groups using Kruskal-Wallis test for continuous variables and chi-square tests for categorical variables. Kaplan-Meier survival analyses were performed to compare time to progression (progressionfree survival-PFS) and death (overall survival -OS) between the groups. Cox proportional hazards regression model was performed to study the contribution of age, gender, histology, TNM status, location of distant metastases and RAI dose with a stepwise variable selection for PFS and OS respectively. Estimated hazard ratios (HR) with corresponding 95% confidence intervals (CI) were reported using the final model. All analyses were twotailed tests based on α = 0.05 and conducted using SAS version 9.4
(SAS Institute, Cary, NC, USA).
| RE SULTS
Of 141 patients with metastatic DTC, 6 patients with initially positive RAI uptake in metastatic lesions had subsequently developed RAI-non-avid metastatic disease. These patients were excluded from the study. Table 1 ). The rhTSH group was characterized by the oldest age at diagnosis, the highest prevalence of follicular thyroid cancer, and bone metastases as well as the lowest prevalence of disease confined to the lungs only, while the THW+Li group was characterized by the highest prevalence of tall cell variant of papillary thyroid cancer. Both rhTSH and THW+Li groups were characterized by similar, and higher than THW group, prevalence of widespread disease with multiple organ involvement ( Table 1 ). The duration of follow-up was similar between the study groups ( Table 1) . During follow-up, THW+Li group received the highest cumulative RAI dosage ( Table 1 ). The highest cumulative dosage most likely relates to the largest number of repeated yearly RAI therapies-median of 4 (P < 0.001) ( Table 1) .
There was no difference in the best overall response to treatment between the study groups (P = 0.11), (Figure 1 Figure 3B ). showing that the method of TSH stimulation did not affect the best overall response to treatment nor PFS. In fact, the only independent factor associated with shorter PFS in that study was patients' older age at diagnosis. 17 The current study found that addition of lithium carbonate to THW is associated with similar best overall response to treatment and PFS as preparation with THW or rhTSH alone.
TA B L E 1 Baseline characteristics of the study groups
There is only one small retrospective case series study involving 12 patients serving as their own historical controls showing similar results. In that study, the patients who failed previous RAI treatments underwent lithium-aided subsequent RAI therapy, without a significant improvement in disease control. 19 Our study documented that the only factor significantly associated with better PFS is presence of metastatic disease confined only to pulmonary metastases. with OS. Our current study shows that endogenous TSH stimulation with adjunct pretreatment with Li is associated with improved OS in patients with metastatic RAI-avid thyroid cancer. However, this observation needs to be interpreted with caution, as the study groups were disbalanced in terms of baseline characteristics, with rhTSH group characterized by the oldest age and both rhTSH and THW+Li group characterized by the most widespread disease.
After adjusting by the factors affecting OS, which were found to be significant in a stepwise logistic regression model, only age and disease burden were found to be strong independent predictors of OS. Of note, the group of patients prepared for RAI with THW and lithium was characterized by the youngest age, most likely contributing to the best OS. Consistent with our findings, the ATA guidelines also underscore that morbidity and mortality in metastatic thyroid cancer are dependent on distribution and number of sites of metastasis, tumour burden, and age at diagnosis of metastases. 1, [22] [23] [24] [25] [26] [27] [28] Interestingly, recent large epidemiological data document that melanoma patients exposed to Li therapy were characterized by lower disease-specific mortality than Li nonexposed melanoma patients (4.68/1000 person-years vs 7.21/1000 person-years, respectively). 29 These data suggest that Li carbonate may exert some pleiotropic effects in cancer patients. It is worthwhile to speculate that these effects might be related to the molecular signature of certain types of cancer. Of note, both thyroid cancer and melanoma are characterized by a high prevalence of BRAFV600E mutation, leading to activation of Raf/MEK/ERK signalling pathway. Lithium is a well-known inhibitor of glycogen synthase kinase-3β, a downstream target of the Raf/MEK/ERK pathway. 30 Recent in vitro studies in leukaemia documented that the antineoplastic effects of Li are MEK/ ERK-dependent. 31 In addition, O'Donovan et al 32 showed that Li modulates autophagy in oesophageal and colorectal cancer leading to improved disease control in vivo when combined with chemotherapeutic agent with more than 50% of the animals achieving longterm cure without re-occurrence (>1-year tumour free). However, relatively short exposure to lithium, of only 7 days preceding each repeated RAI dosage in our cohort, may preclude translation of these observations to our cohort of patients with metastatic thyroid cancer.
Our study has several limitations associated with its design as a cohort study. Moreover, the outcomes of prospective cohort study conducted at the NIH were compared to two retrospective cohorts from another tertiary referral centre. Therefore, as there was no randomization, potential confounders are not equally distributed across the study groups. In fact, we do have an evidence that the groups were disbalanced in terms of age and disease burden. Age and presence of widespread disease with metastases to the brain, spine, kidney and skin are independent prognostic factors associated with decreased overall survival. Disease confined to the pulmonary metastases is associated with better progression-free survival.
F I G U R E 3 A, Significantly longer overall survival (OS) in thyroid hormone withdrawal-lithium (THW-Li) group compared with recombinant human TSH (rhTSH) group (P = 0.007). B, No significant difference in OS THW+Li group compared with rhTSH and THW group after adjustment for factors significantly affecting OS-age and presence of widespread disease with metastases affecting multiple organs, not only the lungs and the bones RAI was an independent factor affecting the outcomes. Although our study was the largest to date addressing potential adjuvant role of lithium therapy in preparation for RAI treatment, it may be underpowered in terms of detection of differences in clinical outcomes.
The other limitation is a lack of additional group of patients prepared for RAI with rhTSH combined with lithium.
| CON CLUS ION
The older age at diagnosis is associated with shorter OS, while disease burden affects both OS and PFS in patients with metastatic differentiated thyroid cancer. The method of preparation for RAI therapy either by exogenous or endogenous TSH stimulation with or without addition of lithium does not significantly affect PFS and OS.
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